Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Terminated 6Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 41Other solid neoplasm 41Gynecologic 7Gastrointestinal 7Breast 6Lymphoid 2Head & Neck 2Genitourinary 2Sarcoma 1NET 1Endocrine 1Dermatologic 1

Conditions

Melanoma 312Carcinoma, Basal Cell 60Skin Neoplasms 53Lymphoma, T-Cell, Cutaneous 37Breast Neoplasms 31Uveal Melanoma 29Neoplasms 27Lung Neoplasms 27Carcinoma, Non-Small-Cell Lung 27Keratosis, Actinic 25Neoplasm Metastasis 24Carcinoma, Squamous Cell 22Carcinoma, Renal Cell 21Lymphoma 17Mycosis Fungoides 16Lymphoma, Large B-Cell, Diffuse 15Hodgkin Disease 15Urinary Bladder Neoplasms 14Sezary Syndrome 14Pancreatic Neoplasms 14Lymphoma, Non-Hodgkin 14Lymphoma, Follicular 14Leukemia, Lymphocytic, Chronic, B-Cell 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Lymphoma, Mantle-Cell 13Lymphoma, B-Cell, Marginal Zone 13Colorectal Neoplasms 13Burkitt Lymphoma 13Lymphoma, Large-Cell, Immunoblastic 12

Interventions

durvalumab 1cemiplimab 1avelumab 1atezolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Mesothelioma, Malignant × Dermatologic × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡